Nanoparticles can overcome drug resistance in breast cancer cells — ScienceDaily
source : http://www.sciencedaily.com/releases/2013/11/131107094031.htm
source : http://www.sciencedaily.com/releases/2013/11/131107094031.htm
Cancer is the second leading cause of death in both men and women in the U.S. However, women have a higher chance than men of being diagnosed with cancer before the age of 60 due to breast cancer development. Metastases in breast cancer’s later stages cause the majority of deaths associated with the disease, making early detection crucial to patient survival. …
The researchers also found that anti-cholesterol drugs such as statins appear to diminish the effect of this estrogen-like molecule. …
If stretched out, the blood vessels in a human body would reach more than twice around the Earth. …
Now, Howard Hughes Medical Institute (HHMI) researchers at the University of California, San Francisco have identified and exploited a newfound "Achilles heel" in K-Ras. The weak point is a newly discovered "pocket," or binding site, identified by HHMI investigator Kevan M. Shokat and colleagues. Shokat and his team have designed a chemical compound that fits inside this pocket and inhibits the normal activity of mutant K-Ras, but leaves the normal protein untouched…
With a New York University Cancer Institute colleague, the researchers report in an upcoming Clinical Chemistry (now online) that the mixture of free-floating blood proteins created by the enzyme carboxypeptidase N accurately predicted the presence of early-stage breast cancer tissue in mice and in a small population of human patients. "In this paper we link the catalytic activity of carboxypeptidase N to tumor progression in clinical samples from breast cancer patients and a breast cancer animal model," said biomedical engineer Tony Hu, Ph.D., who led the project. "Our results indicate that circulating peptides generated by CPN can serve as clear signatures of early disease onset and progression." The technology is not yet available to the public, and may not be for years. More extensive clinical tests are needed, and those tests are expected to begin in early 2014…
Now, an ASU research team led by Biodesign Institute executive director Dr. Ray DuBois, M.D., PhD, has shown that a key genetic culprit, called CXCR2, is implicated in the tumor formation, growth and progression in a mouse model of colon cancer. …
Nanoparticles are just as small, or even smaller, than many blood proteins. …
John Juvik and colleagues explain that diet is one of the most important factors influencing a person’s chances of developing cancer. One of the most helpful food families includes cruciferous vegetables, such as broccoli, kale and cabbage…
Their findings are published in the October 8 issue of the journal Structure, available online now. "Telomerase is a unique protein-RNA complex where the protein subunit uses its RNA component as a template to add identical fragments of DNA to the end of chromosomes," said Emmanuel Skordalakes, Ph.D., associate professor in the Gene Expression and Regulation program of Wistar’s NCI-designated Cancer Center. …